Published in Neurobiol Learn Mem on September 06, 2011
An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Aβ oligomers. J Clin Invest (2012) 2.33
Intracellular amyloid β oligomers impair organelle transport and induce dendritic spine loss in primary neurons. Acta Neuropathol Commun (2015) 1.45
Alzheimer disease therapy--moving from amyloid-β to tau. Nat Rev Neurol (2013) 1.31
Intranasal insulin as a treatment for Alzheimer's disease: a review of basic research and clinical evidence. CNS Drugs (2013) 1.30
Alzheimer's disease, β-amyloid, glutamate, NMDA receptors and memantine--searching for the connections. Br J Pharmacol (2012) 1.26
Cell number changes in Alzheimer's disease relate to dementia, not to plaques and tangles. Brain (2013) 1.20
Inconsistencies and controversies surrounding the amyloid hypothesis of Alzheimer's disease. Acta Neuropathol Commun (2014) 1.16
Alzheimer's disease and insulin resistance: translating basic science into clinical applications. J Clin Invest (2013) 1.12
Amyloid β oligomers in Alzheimer's disease pathogenesis, treatment, and diagnosis. Acta Neuropathol (2015) 1.11
α-Secretase-derived fragment of cellular prion, N1, protects against monomeric and oligomeric amyloid β (Aβ)-associated cell death. J Biol Chem (2011) 1.07
The peculiar role of the A2V mutation in amyloid-β (Aβ) 1-42 molecular assembly. J Biol Chem (2014) 1.04
Inhibition of choline acetyltransferase as a mechanism for cholinergic dysfunction induced by amyloid-β peptide oligomers. J Biol Chem (2012) 0.96
Axonal degeneration in Alzheimer's disease: when signaling abnormalities meet the axonal transport system. Exp Neurol (2012) 0.95
Proteolytic cleavage of apolipoprotein E4 as the keystone for the heightened risk associated with Alzheimer's disease. Int J Mol Sci (2013) 0.95
Towards non-invasive diagnostic imaging of early-stage Alzheimer's disease. Nat Nanotechnol (2014) 0.94
Vitamin D-binding protein interacts with Aβ and suppresses Aβ-mediated pathology. Cell Death Differ (2012) 0.93
Alzheimer-associated Aβ oligomers impact the central nervous system to induce peripheral metabolic deregulation. EMBO Mol Med (2015) 0.92
Amyloid-β oligomers induce differential gene expression in adult human brain slices. J Biol Chem (2012) 0.91
Dysfunction of Wnt signaling and synaptic disassembly in neurodegenerative diseases. J Mol Cell Biol (2014) 0.90
Amyloid-β peptide binds to cytochrome C oxidase subunit 1. PLoS One (2012) 0.89
The triggering receptor expressed on myeloid cells 2: "TREM-ming" the inflammatory component associated with Alzheimer's disease. Oxid Med Cell Longev (2013) 0.89
Indomethacin-loaded lipid-core nanocapsules reduce the damage triggered by Aβ1-42 in Alzheimer's disease models. Int J Nanomedicine (2012) 0.89
Soluble amyloid-β oligomers as synaptotoxins leading to cognitive impairment in Alzheimer's disease. Front Cell Neurosci (2015) 0.89
Clinical trials of intravenous immunoglobulin for Alzheimer's disease. J Clin Immunol (2014) 0.87
Amyloid-β oligomers link depressive-like behavior and cognitive deficits in mice. Mol Psychiatry (2012) 0.87
Amyloid-β Receptors: The Good, the Bad, and the Prion Protein. J Biol Chem (2015) 0.86
Targeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer's disease immunotherapeutics. Alzheimers Res Ther (2014) 0.86
Amyloid-β oligomers induce tau-independent disruption of BDNF axonal transport via calcineurin activation in cultured hippocampal neurons. Mol Biol Cell (2013) 0.85
Metabotropic glutamate receptor 5 knockout reduces cognitive impairment and pathogenesis in a mouse model of Alzheimer's disease. Mol Brain (2014) 0.84
Memantine prevents memory consolidation failure induced by soluble beta amyloid in rats. Front Behav Neurosci (2014) 0.83
Pyroglutamate-Modified Amyloid Beta Peptides: Emerging Targets for Alzheimer´s Disease Immunotherapy. Curr Neuropharmacol (2013) 0.83
Synapse-binding subpopulations of Aβ oligomers sensitive to peptide assembly blockers and scFv antibodies. ACS Chem Neurosci (2012) 0.82
d-serine levels in Alzheimer's disease: implications for novel biomarker development. Transl Psychiatry (2015) 0.82
Brain metabolic stress and neuroinflammation at the basis of cognitive impairment in Alzheimer's disease. Front Aging Neurosci (2015) 0.82
Obesity and diabetes cause cognitive dysfunction in the absence of accelerated β-amyloid deposition in a novel murine model of mixed or vascular dementia. Acta Neuropathol Commun (2014) 0.82
Synaptic deficits in layer 5 neurons precede overt structural decay in 5xFAD mice. Neuroscience (2013) 0.81
From neurodevelopment to neurodegeneration: the interaction of neurofibromin and valosin-containing protein/p97 in regulation of dendritic spine formation. J Biomed Sci (2012) 0.80
Hybrid Graphene Oxide Based Plasmonic-Magnetic Multifunctional Nanoplatform for Selective Separation and Label-Free Identification of Alzheimer's Disease Biomarkers. ACS Appl Mater Interfaces (2015) 0.80
The struggle by Caenorhabditis elegans to maintain proteostasis during aging and disease. Biol Direct (2016) 0.80
A lifespan observation of a novel mouse model: in vivo evidence supports aβ oligomer hypothesis. PLoS One (2014) 0.79
Mesenchymal Stem Cells Preserve Working Memory in the 3xTg-AD Mouse Model of Alzheimer's Disease. Int J Mol Sci (2016) 0.79
L-Stepholidine rescues memory deficit and synaptic plasticity in models of Alzheimer's disease via activating dopamine D1 receptor/PKA signaling pathway. Cell Death Dis (2015) 0.79
Atorvastatin prevents Aβ oligomer-induced neurotoxicity in cultured rat hippocampal neurons by inhibiting Tau cleavage. Acta Pharmacol Sin (2015) 0.79
Epistasis analysis links immune cascades and cerebral amyloidosis. J Neuroinflammation (2015) 0.79
Novel roles of amyloid-beta precursor protein metabolites in fragile X syndrome and autism. Mol Psychiatry (2016) 0.79
Rescue of amyloid-Beta-induced inhibition of nicotinic acetylcholine receptors by a peptide homologous to the nicotine binding domain of the alpha 7 subtype. PLoS One (2013) 0.78
Dendritic and axonal mechanisms of Ca2+ elevation impair BDNF transport in Aβ oligomer-treated hippocampal neurons. Mol Biol Cell (2015) 0.78
Calcium-Sensing Receptors of Human Neural Cells Play Crucial Roles in Alzheimer's Disease. Front Physiol (2016) 0.78
Developing BACE-1 inhibitors for FXS. Front Cell Neurosci (2013) 0.78
Oridonin Attenuates Synaptic Loss and Cognitive Deficits in an Aβ1-42-Induced Mouse Model of Alzheimer's Disease. PLoS One (2016) 0.77
Amyloid-β-Induced Dysregulation of AMPA Receptor Trafficking. Neural Plast (2016) 0.77
Amyloidβ Peptides in interaction with raft-mime model membranes: a neutron reflectivity insight. Sci Rep (2016) 0.77
Protein Tyrosine Phosphatase 1B (PTP1B): A Potential Target for Alzheimer's Therapy? Front Aging Neurosci (2017) 0.77
A combination Alzheimer's therapy targeting BACE1 and neprilysin in 5XFAD transgenic mice. Mol Brain (2015) 0.77
Therapeutic potential of mGluR5 targeting in Alzheimer's disease. Front Neurosci (2015) 0.77
Evidence for Alzheimer's disease-linked synapse loss and compensation in mouse and human hippocampal CA1 pyramidal neurons. Brain Struct Funct (2014) 0.77
Central and peripheral administration of antisense oligonucleotide targeting amyloid-β protein precursor improves learning and memory and reduces neuroinflammatory cytokines in Tg2576 (AβPPswe) mice. J Alzheimers Dis (2014) 0.77
Effects of BACE1 haploinsufficiency on APP processing and Aβ concentrations in male and female 5XFAD Alzheimer mice at different disease stages. Neuroscience (2015) 0.77
Modulation of amyloid-β aggregation by histidine-coordinating Cobalt(III) Schiff base complexes. Chembiochem (2014) 0.76
Interaction of Aβ Oligomers with Neurexin 2α and Neuroligin 1 Mediates Synapse Damage and Memory Loss in Mice. J Biol Chem (2017) 0.75
Amyloid β-peptide oligomers, ryanodine receptor-mediated Ca(2+) release, and Wnt-5a/Ca(2+) signaling: opposing roles in neuronal mitochondrial dynamics? Front Cell Neurosci (2013) 0.75
APP Causes Hyperexcitability in Fragile X Mice. Front Mol Neurosci (2016) 0.75
Overexpression of EphB2 in hippocampus rescues impaired NMDA receptors trafficking and cognitive dysfunction in Alzheimer model. Cell Death Dis (2017) 0.75
Parishin C's prevention of Aβ 1-42-induced inhibition of long-term potentiation is related to NMDA receptors. Acta Pharm Sin B (2016) 0.75
Otophylloside B Protects Against Aβ Toxicity in Caenorhabditis elegans Models of Alzheimer's Disease. Nat Prod Bioprospect (2017) 0.75
Alternative Splicing in Alzheimer's Disease. J Parkinsons Dis Alzheimers Dis (2015) 0.75
The Biological Function of the Prion Protein: A Cell Surface Scaffold of Signaling Modules. Front Mol Neurosci (2017) 0.75
Alzheimer's Toxic Amyloid Beta Oligomers: Unwelcome Visitors to the Na/K ATPase alpha3 Docking Station. Yale J Biol Med (2017) 0.75
Wnt Signaling Prevents the Aβ Oligomer-Induced Mitochondrial Permeability Transition Pore Opening Preserving Mitochondrial Structure in Hippocampal Neurons. PLoS One (2017) 0.75
The Hsp70/Hsp90 Chaperone Machinery in Neurodegenerative Diseases. Front Neurosci (2017) 0.75
The Role of BiP Retrieval by the KDEL Receptor in the Early Secretory Pathway and its Effect on Protein Quality Control and Neurodegeneration. Front Mol Neurosci (2017) 0.75
Neuroprotective astrocyte-derived insulin/insulin-like growth factor 1 stimulates endocytic processing and extracellular release of neuron-bound Aβ oligomers. Mol Biol Cell (2017) 0.75
Neuroprotective astrocyte-derived insulin/IGF-1 stimulate endocytic processing and extracellular release of neuron-bound Aβ oligomers. Mol Biol Cell (2017) 0.75
Presenilin-1 Targeted Morpholino Induces Cognitive Deficits, Increased Brain Aβ1-42 and Decreased Synaptic Marker PSD-95 in Zebrafish Larvae. Neurochem Res (2017) 0.75
Fucoxanthin, a Marine Carotenoid, Attenuates β-Amyloid Oligomer-Induced Neurotoxicity Possibly via Regulating the PI3K/Akt and the ERK Pathways in SH-SY5Y Cells. Oxid Med Cell Longev (2017) 0.75
Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science (1993) 33.32
Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun (1984) 20.07
Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature (2002) 19.36
Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science (2003) 18.18
Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med (2008) 17.09
The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology (1989) 16.83
Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature (1991) 16.77
A specific amyloid-beta protein assembly in the brain impairs memory. Nature (2006) 16.19
Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A (1998) 16.04
Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet (2009) 15.15
Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A (1993) 15.04
Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol (2003) 14.87
Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol (1991) 14.25
Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron (2003) 14.03
Alzheimer's disease: the amyloid cascade hypothesis. Science (1992) 13.80
Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature (1995) 13.80
High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci (2000) 9.85
Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci (2004) 9.73
Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci (2005) 9.17
The mGluR theory of fragile X mental retardation. Trends Neurosci (2004) 8.88
Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci (2007) 8.27
PDZ domain proteins of synapses. Nat Rev Neurosci (2004) 8.14
Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science (2010) 8.04
Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology (1999) 7.55
Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron (2005) 7.53
Single-molecule microscopy reveals plasma membrane microdomains created by protein-protein networks that exclude or trap signaling molecules in T cells. Cell (2005) 7.27
Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature (2009) 6.99
Neural consequences of environmental enrichment. Nat Rev Neurosci (2000) 6.79
AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss. Neuron (2006) 6.76
Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J Neurosci (2006) 6.52
Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. Nature (1992) 6.51
Alternative pathway of insulin signalling in mice with targeted disruption of the IRS-1 gene. Nature (1994) 6.50
Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci (2007) 6.27
Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci U S A (1993) 5.68
Amyloid beta -protein (Abeta) assembly: Abeta 40 and Abeta 42 oligomerize through distinct pathways. Proc Natl Acad Sci U S A (2002) 5.46
Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature (2002) 5.32
Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron (1996) 5.30
Synaptic targeting by Alzheimer's-related amyloid beta oligomers. J Neurosci (2004) 5.10
Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci (2002) 5.01
Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science (2009) 4.92
The genetics of Alzheimer disease: back to the future. Neuron (2010) 4.91
Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci U S A (2003) 4.80
Inhibition of activity-dependent arc protein expression in the rat hippocampus impairs the maintenance of long-term potentiation and the consolidation of long-term memory. J Neurosci (2000) 4.55
The fragile X syndrome protein FMRP associates with BC1 RNA and regulates the translation of specific mRNAs at synapses. Cell (2003) 4.34
Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. Proc Natl Acad Sci U S A (1994) 4.33
Dendritic spine pathology: cause or consequence of neurological disorders? Brain Res Brain Res Rev (2002) 4.31
Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J Biol Chem (2005) 4.23
Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology (2007) 4.14
Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat Med (1997) 4.10
Soluble oligomers of amyloid Beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron (2009) 3.94
Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease--is this type 3 diabetes? J Alzheimers Dis (2005) 3.78
Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers. J Physiol (2006) 3.74
Amyloid-β protein oligomerization and the importance of tetramers and dodecamers in the aetiology of Alzheimer's disease. Nat Chem (2009) 3.66
Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Arch Gen Psychiatry (2010) 3.64
Signal-processing machines at the postsynaptic density. Science (2000) 3.47
In vitro aging of beta-amyloid protein causes peptide aggregation and neurotoxicity. Brain Res (1991) 3.45
Memory impairment in transgenic Alzheimer mice requires cellular prion protein. J Neurosci (2010) 3.36
Reversing EphB2 depletion rescues cognitive functions in Alzheimer model. Nature (2010) 3.36
Insulin resistance is associated with the pathology of Alzheimer disease: the Hisayama study. Neurology (2010) 3.35
Abeta oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J Biol Chem (2007) 3.35
The secretases: enzymes with therapeutic potential in Alzheimer disease. Nat Rev Neurol (2010) 3.32
Intraneuronal Alzheimer abeta42 accumulates in multivesicular bodies and is associated with synaptic pathology. Am J Pathol (2002) 3.23
Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model. Neuron (2004) 3.21
Picomolar amyloid-beta positively modulates synaptic plasticity and memory in hippocampus. J Neurosci (2008) 3.21
Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J Neurosci (2002) 3.20
Alzheimer disease amyloid beta protein forms calcium channels in bilayer membranes: blockade by tromethamine and aluminum. Proc Natl Acad Sci U S A (1993) 3.16
Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. Proc Natl Acad Sci U S A (2005) 3.15
Precursor of amyloid protein in Alzheimer disease undergoes fast anterograde axonal transport. Proc Natl Acad Sci U S A (1990) 3.13
Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proc Natl Acad Sci U S A (2011) 3.11
Amyloid beta protein forms ion channels: implications for Alzheimer's disease pathophysiology. FASEB J (2001) 3.08
Globular amyloid beta-peptide oligomer - a homogenous and stable neuropathological protein in Alzheimer's disease. J Neurochem (2005) 3.06
Probing the biology of Alzheimer's disease in mice. Neuron (2010) 2.96
Insulin signaling in health and disease. Science (2003) 2.93
Syntaxin-4 defines a domain for activity-dependent exocytosis in dendritic spines. Cell (2010) 2.88
Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res (2002) 2.88
Neuropathology and cognitive impairment in Alzheimer disease: a complex but coherent relationship. J Neuropathol Exp Neurol (2009) 2.87
Synthetic amyloid-beta oligomers impair long-term memory independently of cellular prion protein. Proc Natl Acad Sci U S A (2010) 2.86
Self-assembly of Abeta(1-42) into globular neurotoxins. Biochemistry (2003) 2.85
Inhaled anesthetic enhancement of amyloid-beta oligomerization and cytotoxicity. Anesthesiology (2004) 2.82
Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization. J Neurosci (2008) 2.77
FMRP mediates mGluR5-dependent translation of amyloid precursor protein. PLoS Biol (2007) 2.75
Beta-amyloid accumulation in APP mutant neurons reduces PSD-95 and GluR1 in synapses. Neurobiol Dis (2005) 2.70
Down patients: extracellular preamyloid deposits precede neuritic degeneration and senile plaques. Neurosci Lett (1989) 2.69
Physiology of the prion protein. Physiol Rev (2008) 2.65
Amyloid beta -peptide inhibition of the PKA/CREB pathway and long-term potentiation: reversibility by drugs that enhance cAMP signaling. Proc Natl Acad Sci U S A (2002) 2.57
Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. FASEB J (2004) 2.56
Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease. A link between Abeta and tau pathology. J Biol Chem (2005) 2.56
Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers. Proc Natl Acad Sci U S A (2009) 2.50
Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation. Neurobiol Dis (1996) 2.50
Giant multilevel cation channels formed by Alzheimer disease amyloid beta-protein [A beta P-(1-40)] in bilayer membranes. Proc Natl Acad Sci U S A (1993) 2.41
Deleterious effects of amyloid beta oligomers acting as an extracellular scaffold for mGluR5. Neuron (2010) 2.34
Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer's disease. J Neurosci (2005) 2.34
Soluble Aβ oligomers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors. J Neurosci (2011) 2.33
Clusterin (apoJ) alters the aggregation of amyloid beta-peptide (A beta 1-42) and forms slowly sedimenting A beta complexes that cause oxidative stress. Exp Neurol (1995) 2.33
Monoclonal antibodies that target pathological assemblies of Abeta. J Neurochem (2006) 2.32
Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol Aging (2010) 2.32
Insulin receptor signaling regulates synapse number, dendritic plasticity, and circuit function in vivo. Neuron (2008) 2.25
Amyloid beta oligomers induce impairment of neuronal insulin receptors. FASEB J (2007) 2.25
Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci (2007) 6.27
Synaptic targeting by Alzheimer's-related amyloid beta oligomers. J Neurosci (2004) 5.10
Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci U S A (2003) 4.80
Abeta oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J Biol Chem (2007) 3.35
Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. Proc Natl Acad Sci U S A (2005) 3.15
Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res (2002) 2.88
Self-assembly of Abeta(1-42) into globular neurotoxins. Biochemistry (2003) 2.85
Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease. A link between Abeta and tau pathology. J Biol Chem (2005) 2.56
Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers. Proc Natl Acad Sci U S A (2009) 2.50
Deleterious effects of amyloid beta oligomers acting as an extracellular scaffold for mGluR5. Neuron (2010) 2.34
An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Aβ oligomers. J Clin Invest (2012) 2.33
Modeling Alzheimer's disease with iPSCs reveals stress phenotypes associated with intracellular Aβ and differential drug responsiveness. Cell Stem Cell (2013) 2.32
Monoclonal antibodies that target pathological assemblies of Abeta. J Neurochem (2006) 2.32
Amyloid beta oligomers induce impairment of neuronal insulin receptors. FASEB J (2007) 2.25
A mouse model of amyloid beta oligomers: their contribution to synaptic alteration, abnormal tau phosphorylation, glial activation, and neuronal loss in vivo. J Neurosci (2010) 2.22
Detection of a biomarker for Alzheimer's disease from synthetic and clinical samples using a nanoscale optical biosensor. J Am Chem Soc (2005) 2.21
Alzheimer's disease-type neuronal tau hyperphosphorylation induced by A beta oligomers. Neurobiol Aging (2007) 1.99
TNF-α mediates PKR-dependent memory impairment and brain IRS-1 inhibition induced by Alzheimer's β-amyloid oligomers in mice and monkeys. Cell Metab (2013) 1.74
Temporal memory deficits in Alzheimer's mouse models: rescue by genetic deletion of BACE1. Eur J Neurosci (2006) 1.69
Amyloid-beta-induced pathological behaviors are suppressed by Ginkgo biloba extract EGb 761 and ginkgolides in transgenic Caenorhabditis elegans. J Neurosci (2006) 1.66
Ibuprofen reduces Abeta, hyperphosphorylated tau and memory deficits in Alzheimer mice. Brain Res (2008) 1.56
Females exhibit more extensive amyloid, but not tau, pathology in an Alzheimer transgenic model. Brain Res (2008) 1.51
Selective neuronal degeneration induced by soluble oligomeric amyloid beta protein. FASEB J (2002) 1.48
Aβ oligomer-induced synapse degeneration in Alzheimer's disease. Cell Mol Neurobiol (2011) 1.33
Intraneuronal amyloid β oligomers cause cell death via endoplasmic reticulum stress, endosomal/lysosomal leakage, and mitochondrial dysfunction in vivo. J Neurosci Res (2011) 1.26
Insulin receptor dysfunction impairs cellular clearance of neurotoxic oligomeric a{beta}. J Biol Chem (2009) 1.21
CCL2 accelerates microglia-mediated Abeta oligomer formation and progression of neurocognitive dysfunction. PLoS One (2009) 1.21
ADDLs and the signaling web that leads to Alzheimer's disease. Neuropharmacology (2010) 1.18
PGH2-derived levuglandin adducts increase the neurotoxicity of amyloid beta1-42. J Neurochem (2006) 1.12
Femtomole immunodetection of synthetic and endogenous amyloid-beta oligomers and its application to Alzheimer's disease drug candidate screening. J Mol Neurosci (2003) 1.12
Amyloid β oligomers in Alzheimer's disease pathogenesis, treatment, and diagnosis. Acta Neuropathol (2015) 1.11
N-methyl-D-aspartate receptors are required for synaptic targeting of Alzheimer's toxic amyloid-β peptide oligomers. J Neurochem (2010) 1.10
Different β-amyloid oligomer assemblies in Alzheimer brains correlate with age of disease onset and impaired cholinergic activity. Neurobiol Aging (2011) 1.09
Alzheimer's-associated Abeta oligomers show altered structure, immunoreactivity and synaptotoxicity with low doses of oleocanthal. Toxicol Appl Pharmacol (2009) 1.08
FcγRIIb mediates amyloid-β neurotoxicity and memory impairment in Alzheimer's disease. J Clin Invest (2013) 1.08
The E693Delta mutation in amyloid precursor protein increases intracellular accumulation of amyloid beta oligomers and causes endoplasmic reticulum stress-induced apoptosis in cultured cells. Am J Pathol (2009) 1.07
Salvianolic acid B inhibits Abeta fibril formation and disaggregates preformed fibrils and protects against Abeta-induced cytotoxicty. Neurochem Int (2007) 1.04
AAV1/2-mediated CNS gene delivery of dominant-negative CCL2 mutant suppresses gliosis, beta-amyloidosis, and learning impairment of APP/PS1 mice. Mol Ther (2009) 0.98
Amyloid-β triggers the release of neuronal hexokinase 1 from mitochondria. PLoS One (2010) 0.98
Intracellular Aβ-oligomers and early inflammation in a model of Alzheimer's disease. Neurobiol Aging (2011) 0.97
Inhibition of choline acetyltransferase as a mechanism for cholinergic dysfunction induced by amyloid-β peptide oligomers. J Biol Chem (2012) 0.96
Stimulation of neurogenesis and synaptogenesis by bilobalide and quercetin via common final pathway in hippocampal neurons. J Alzheimers Dis (2009) 0.94
Endoplasmic reticulum stress occurs downstream of GluN2B subunit of N-methyl-d-aspartate receptor in mature hippocampal cultures treated with amyloid-β oligomers. Aging Cell (2012) 0.93
Memantine rescues transient cognitive impairment caused by high-molecular-weight aβ oligomers but not the persistent impairment induced by low-molecular-weight oligomers. J Neurosci (2013) 0.93
Conformation-dependent single-chain variable fragment antibodies specifically recognize beta-amyloid oligomers. FEBS Lett (2009) 0.91
Amyloid-β and tau pathology of Alzheimer's disease induced by diabetes in a rabbit animal model. J Alzheimers Dis (2012) 0.90
Per-6-substituted-per-6-deoxy beta-cyclodextrins inhibit the formation of beta-amyloid peptide derived soluble oligomers. J Med Chem (2004) 0.90
Hypercholesterolemia accelerates intraneuronal accumulation of Aβ oligomers resulting in memory impairment in Alzheimer's disease model mice. Life Sci (2012) 0.89
Targeting generation of antibodies specific to conformational epitopes of amyloid beta-derived neurotoxins. CNS Neurol Disord Drug Targets (2009) 0.88
Brain transit and ameliorative effects of intranasally delivered anti-amyloid-β oligomer antibody in 5XFAD mice. J Alzheimers Dis (2013) 0.87
Soluble state high resolution atomic force microscopy study of Alzheimer's beta-amyloid oligomers. Appl Phys Lett (2009) 0.86
Heat shock treatment reduces beta amyloid toxicity in vivo by diminishing oligomers. Neurobiol Aging (2008) 0.85
Detection and Identification of Bioanalytes with High Resolution LSPR Spectroscopy and MALDI Mass Spectrometry. J Phys Chem C Nanomater Interfaces (2009) 0.83
Nanodisc-solubilized membrane protein library reflects the membrane proteome. Anal Bioanal Chem (2013) 0.83
Intracellular Aβ pathology and early cognitive impairments in a transgenic rat overexpressing human amyloid precursor protein: a multidimensional study. Acta Neuropathol Commun (2014) 0.82
Synapse-binding subpopulations of Aβ oligomers sensitive to peptide assembly blockers and scFv antibodies. ACS Chem Neurosci (2012) 0.82
Novel demonstration of amyloid-β oligomers in sporadic inclusion-body myositis muscle fibers. Acta Neuropathol (2010) 0.81
Cyclic AMP enhancers and Abeta oligomerization blockers as potential therapeutic agents in Alzheimer's disease. Curr Alzheimer Res (2007) 0.81
Protection against the synaptic targeting and toxicity of Alzheimer's-associated Aβ oligomers by insulin mimetic chiro-inositols. FASEB J (2012) 0.81
Per-6-substituted beta-cyclodextrin libraries inhibit formation of beta-amyloid-peptide (A beta)-derived, soluble oligomers. J Mol Neurosci (2002) 0.78
Elucidating molecular mass and shape of a neurotoxic Aβ oligomer. ACS Chem Neurosci (2014) 0.78
Aβ oligomers-induced toxicity is attenuated in cells cultured with NbActiv4™ medium. Neurotox Res (2012) 0.77
Disruption of neocortical histone H3 homeostasis by soluble Aβ: implications for Alzheimer's disease. Neurobiol Aging (2013) 0.77
Modulation of amyloid-β aggregation by histidine-coordinating Cobalt(III) Schiff base complexes. Chembiochem (2014) 0.76
Accumulation of intraneuronal amyloid-β is common in normal brain. Curr Alzheimer Res (2014) 0.76
A Study of Aβ Oligomers in the Temporal Cortex and Cerebellum of Patients with Neuropathologically Confirmed Alzheimer's Disease Compared to Aged Controls. Neurodegener Dis (2016) 0.75